NY-AQARA
22.9.2021 10:02:12 CEST | Business Wire | Press release
Aqara, a provider for smart home products, announced the launch of the Aqara Roller Shade Driver E1, a retrofit roller shade controller to automate the existing beaded chain roller shades. The roller shade driver fits beaded cord roller shades with the bead thickness of 3 - 6 millimeter, and works with both plastic and metal beads. The driver has been available on Amazon UK starting from September 22, 2021, and it is expected to land on Amazon France in the next few weeks. It will also be made available via authorized Aqara retailers in Europe and Asia in the following months.
Shades are necessary for almost all homes, as they block harmful UV rays, save energy (for ACs and lights) and protect privacy. Automated shades save users the trouble of manually controlling the shades day in and day out, while helping to cut energy bills and enhance indoor comfort.
The Roller Shade Driver E1 provides a quick, easy and cost-effective way to automate the existing roller blinds. The installation is simple, as it does not require dedicated wiring. Just screw the device to the wall, insert the beaded chain of the roller shade, and the driver will be ready to be connected. The roller shade driver can be charged wirelessly from the built-in battery (2-month battery life per charge1 ), or be plugged into a constant power supply via the provided USB Type-C cable, offering high installation flexibility to users. Four adapters for different types of beaded chains are provided, so that the driver could work with a majority of beaded chain roller shades.
The roller shade driver supports the latest Zigbee 3.0 protocol, and it can be bound with an Aqara hub2 to work with other Aqara child devices, enabling smart home scenes and automations. It is also compatible with major ecosystems including Apple HomeKit, Amazon Alexa, Google Home, and more3 .
With this roller shade driver, users can not only control the roller shades by wireless remote switches and voice commands, they can also configure home automations such as rolling down the blinds automatically when the sun is too bright, or when the user goes to bed at nights.
To celebrate the launch, Aqara now offers a 15% discount for the Roller Shade Driver E1 on its Amazon UK store with the promo code: RSDE1PR1, and the offering will be valid through September 24, 2021.
Moreover, the Roller Shade Driver E1 will be released to the Aqara brand store on Amazon.fr in the next few weeks. It is also expected to be made available in various European and Asian countries via authorized Aqara retailers in the following months. Please check with the regional retailer(s) for product availability.
For more details of the roller shade driver, please visit our website .
1 Based on the assumption of rolling up and down a roller shade of 1.8m*1.8m once a day
2 A compatible Zigbee 3.0 Aqara hub (including Hub M1S, Hub M2 and Camera Hub G2H) is required.
3 Integration with some third-party ecosystems may be unavailable by the time of the launch.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210922005355/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom